Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Trial details
- Registry ID
- NCT06846541
- Drugs studied
- Blinded Envudeucitinib, Open-Label Envudeucitinib
TrialRedline tracks 7 clinical trials sponsored by Alumis Inc: 3 Phase 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque PsoriasisNCT06846541 | Blinded Envudeucitinib, Open-Label Envudeucitinib | Active not recruiting | 2028-11Estimated |
| A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001NCT06588738 | Apremilast, Envudeucitinib | Completed | 2025-09-23Actual |
| A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisNCT06586112 | Apremilast, Envudeucitinib | Completed | 2025-09-19Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque PsoriasisNCT05739435 | envudeucitinib | Active not recruiting | 2027-12-01Estimated |
| Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusNCT05966480 | Envudeucitinib | Active not recruiting | 2026-06-23Actual |
| A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque PsoriasisNCT05600036 | ESK-001 | Completed | 2023-06-29Actual |
| POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUNCT05953688 | ESK-001 | Terminated | 2024-08-13Actual |
Names as written in the registry records.
Before: 1 Dec 2026. After: 1 Dec 2027.
Before: Estimated. After: Actual.
Before: 1 Jul 2026. After: 23 Jun 2026.
Before: Estimated. After: Actual.
Before: 840 participants (planned). After: 862 participants (actual).
Before: Active not recruiting. After: Completed.
Before: Estimated. After: Actual.
Before: 840 participants (planned). After: 912 participants (actual).
Before: Active not recruiting. After: Completed.
NCT06846541 · Alumis Inc
Before: Recruiting. After: Active not recruiting.